Myriad Genetics (MYGN) – Company Press Releases
-
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
-
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
-
Myriad Genetics to Participate in Stephens Annual Investment Conference
-
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
-
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
-
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
-
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
-
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
-
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
-
BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD
-
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
-
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
-
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
-
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
-
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
-
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
-
Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference
-
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
-
Myriad Genetics to Host Investor Day on September 19, 2023
-
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
-
Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment
-
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
-
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volu
-
Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
-
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
-
Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
-
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
-
Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
-
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
-
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
-
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
-
Myriad Genetics Earns 2023 Great Place to Work Certification™
-
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point
-
Myriad Genetics to Participate in BofA Securities Healthcare Conference
-
Myriad Genetics to Participate in BofA Securities Healthcare Conference
-
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
-
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
-
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
-
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
-
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
-
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
-
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
-
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
-
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
-
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
-
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
-
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
-
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
-
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight
-
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight
Back to MYGN Stock Lookup
